Skip to content

Delcath Systems DCTH Operating lease right-of-use asset amortization

Operating lease right-of-use asset amortization at other companies

Merit Medical Systems logo
Merit Medical SystemsMMSI
Immunome logo
ImmunomeIMNM
Arcus Biosciences logo
Arcus BiosciencesRCUS
Viking Therapeutics logo
Viking TherapeuticsVKTX
Fulgent Genetics, Inc. logo
Fulgent Genetics, Inc.FLGT

Other financials

Income statement

See full
Revenue$25.0M+26.3%
Gross profit$21.3M+25.5%
Operating income-$1.6M-355%
Net income-$1.1M-200%
EPS (diluted)-$0.03-200%

Balance sheet

See full
Cash & equivalents$41.3M+223%
Total debt$907.0K-10.7%
Total equity$112.7M+40.5%
Total assets$124.8M+43.0%

Cash flow

See full
Operating cash flow$857.0K-61.1%
CapEx$570.0K+307%
Free cash flow$287.0K-86.1%

Valuation

See full
Market cap$425.31M-11.8%
Enterprise value$384.91M-18.2%
P/E120.6×
P/S4.7×-4.3×

Profitability

See full
Gross margin86%+1.1pp
Operating margin-118.1%-56.8pp
Net margin1.5%+0.8pp
FCF margin21.2%+15.2pp

Returns & leverage

See full
Return on equity1.9%+1.0pp
Debt / equity0.0×
Current ratio11.2×-4.7×

Where this comes from

Reported directly by Delcath Systems in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: Delcath Systems’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Delcath Systems's operating lease right-of-use asset amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Delcath Systems's operating lease right-of-use asset amortization?
Delcath Systems (DCTH) reported operating lease right-of-use asset amortization of $29K in Q1 2026.
How has Delcath Systems's operating lease right-of-use asset amortization changed year-over-year?
Delcath Systems's operating lease right-of-use asset amortization increased by 20.8% year-over-year, from $24K to $29K.